% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
%
\documentclass[
]{article}
\usepackage{lmodern}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math}
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\makeatletter
\@ifundefined{KOMAClassName}{% if non-KOMA class
  \IfFileExists{parskip.sty}{%
    \usepackage{parskip}
  }{% else
    \setlength{\parindent}{0pt}
    \setlength{\parskip}{6pt plus 2pt minus 1pt}}
}{% if KOMA class
  \KOMAoptions{parskip=half}}
\makeatother
\usepackage{xcolor}
\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}}
\hypersetup{
  hidelinks,
  pdfcreator={LaTeX via pandoc}}
\urlstyle{same} % disable monospaced font for URLs
\usepackage[margin=1.5cm]{geometry}
\usepackage{graphicx,grffile}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
% Set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother
\setlength{\emergencystretch}{3em} % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{5}
\usepackage[utf8]{inputenc}
\usepackage[T1]{fontenc}
\usepackage{chngcntr}


 \usepackage{multirow}
 \usepackage{wrapfig}
 \usepackage{float}
 
 
\usepackage{booktabs}
\usepackage{longtable}
\usepackage{lscape}
\usepackage{array}
\usepackage{rotating}
\usepackage{multirow}

\usepackage{babel}
 
% \let\origfigure\figure
% \let\endorigfigure\endfigure
% \renewenvironment{figure}[1][2] {
%     \expandafter\origfigure\expandafter[H]
% } {
%     \endorigfigure
% }
 
 \usepackage{colortbl}
 \usepackage{tabu}
 \usepackage{threeparttable}
 \usepackage{threeparttablex}
 \usepackage[normalem]{ulem}
 \usepackage{makecell}
 \floatplacement{figure}{H} % see https://stackoverflow.com/questions/42486617/knitr-ignoring-fig-pos
 \usepackage{dcolumn}
\usepackage{rotating}

\usepackage{lscape}

\usepackage{xcolor}
\usepackage{adjustbox}
\usepackage{hyperref}

% Source: https://tex.stackexchange.com/questions/82993/how-to-change-the-name-of-document-elements-like-figure-contents-bibliogr
%\renewcommand{\bibname}{References}

\newcommand{\blandscape}{\begin{landscape}}
\newcommand{\elandscape}{\end{landscape}}


%https://stackoverflow.com/questions/51633434/prevent-pagebreak-in-kableextra-landscape-table
\usepackage[graphicx]{realboxes}  

\let\origfigure\figure
\let\endorigfigure\endfigure
\renewenvironment{figure}[1][2] {
    \expandafter\origfigure\expandafter[H]
} {
    \endorigfigure
}

%https://stackoverflow.com/questions/16626462/figure-position-in-markdown-when-converting-to-pdf-with-knitr-and-pandoc


% see https://tex.stackexchange.com/questions/63030/change-color-and-background-behind-text-of-all-description-environments


\newenvironment{cdescription}{%
  \begin{adjustbox}{minipage=\linewidth,bgcolor=blue,vspace=\smallskipamount}
    \begin{description}
      \color{red}%
}{%
    \end{description}
  \end{adjustbox}
}


% Source: https://tex.stackexchange.com/questions/30757/change-the-word-chapter-to-something-else
% uncomment if using for bookdown
\usepackage{fancyhdr}
% \makeatletter
% \renewcommand{\@chapapp}{Section}
% \makeatother


% see http://tex.stackexchange.com/questions/184080/using-beamer-bullets-in-poster
\usepackage{tikz}
\usetikzlibrary{arrows.meta,positioning,decorations.markings,shapes}
\tikzset{
font={\fontsize{14pt}{16}\selectfont}}


\tikzset{
            gla/.style={
          , line width=0.5mm, arrows={-Stealth[angle=45:12pt, scale=1, black, fill=black]}}}
          
\tikzset{
            dgla/.style={
          , line width=0.5mm, shorten >=1pt, arrows={Stealth-Stealth[angle=45:10pt, scale=1, black, fill=black]}}}

\tikzset{
    ultra thin/.style= {line width=0.1pt},
    very thin/.style=  {line width=0.2pt},
    thin/.style=       {line width=0.4pt},% thin is the default
    rec/.style=        {shape=rectangle, line width=0.5mm, draw},% thin is the default
    semithick/.style=  {line width=0.6pt},
    thick/.style=      {line width=0.8pt},
    very thick/.style= {line width=1.2pt},
    ultra thick/.style={line width=1.6pt}
}  

% Source: https://latex.org/forum/viewtopic.php?t=15908
\newcolumntype{C}[1]{>{\centering\arraybackslash}m{#1}}

% NOTE: the following does not work
% Source: https://tex.stackexchange.com/questions/249346/reduce-white-space-above-chapter-title-and-reduce-space-between-title-and-text/249370

%%% Add this %%%
% \usepackage{titlesec}
% \titleformat{\chapter}[display]
% {\normalfont\huge\bfseries}{\chaptertitlename~\thechapter}{20pt}{\Huge}
% \titlespacing*{\chapter}{0pt}{50pt}{40pt}
% \titlespacing*{name=\chapter,numberless}{0pt}{-30pt}{10pt}
%%%   End   %%%



\newcommand{\beginsupplement}{
  \setcounter{table}{0}  
  \renewcommand{\thetable}{S\arabic{table}} 
  \setcounter{figure}{0} 
  \renewcommand{\thefigure}{S\arabic{figure}}
}

% Source: https://stackoverflow.com/questions/52118202/change-line-spacing-for-rmd-abstract
\usepackage{setspace}\doublespacing
% https://github.com/rstudio/rmarkdown/issues/337
\let\rmarkdownfootnote\footnote%
\def\footnote{\protect\rmarkdownfootnote}

% https://github.com/rstudio/rmarkdown/pull/252
\usepackage{titling}
\setlength{\droptitle}{-2em}

\pretitle{\vspace{\droptitle}\centering\huge}
\posttitle{\par}

\preauthor{\centering\large\emph}
\postauthor{\par}

\predate{\centering\large\emph}
\postdate{\par}
\usepackage{booktabs}
\usepackage{longtable}
\usepackage{array}
\usepackage{multirow}
\usepackage{wrapfig}
\usepackage{float}
\usepackage{colortbl}
\usepackage{pdflscape}
\usepackage{tabu}
\usepackage{threeparttable}
\usepackage{threeparttablex}
\usepackage[normalem]{ulem}
\usepackage{makecell}
\usepackage{xcolor}

\date{}

\begin{document}

\singlespace

\hypertarget{tables}{%
\section{Tables}\label{tables}}

\begin{longtable}[t]{llll}
\caption{\label{tab:unnamed-chunk-4}Baseline characteristics of subcohort and cases of breast cancer}\\
\toprule
\multicolumn{2}{c}{ } & \multicolumn{2}{c}{Case-cohort} \\
\cmidrule(l{3pt}r{3pt}){3-4}
Variable & Total & Subcohort (no cases) & Cases\\
\midrule
n & 50884 & 2952 & 2974\\
Baseline age (years) & 56 [49, 62] & 55 [49, 62] & 57 [50, 64]\\
BMI (kg/m$^2$) & 27 [23, 31] & 27 [23, 31] & 27 [24, 31]\\
Waist circumference (in) & 33 [30, 38] & 33 [30, 37] & 34 [30, 38]\\
Height (cm) & 65 [63, 66] & 64 [63, 66] & 65 [63, 66]\\
Age at menarche (years) & 13 [12, 13] & 13 [12, 13] & 13 [12, 13]\\
Time since menopause (years) & 4 [0, 12] & 4 [0, 12] & 6 [0, 13]\\
Iron (mcg/dL) &  & 92 [73, 115] & 93 [75, 116]\\
Ferritin (mcg/dL) &  & 67 [36, 112] & 70 [38, 116]\\
Iron saturation (\%) &  & 28 [22, 36] & 29 [22, 36]\\
TIBC &  & 328 [300, 360] & 328 [299, 360]\\
UIBC &  & 231 [197, 269] & 231 [196, 269]\\
Baseline menopause status &  &  & \\
\hspace{1em}No menopause & 17892 (35) & 1055 (36) & 932 (31)\\
\hspace{1em}age<=45 years & 5952 (12) & 343 (12) & 280 (9)\\
\hspace{1em}age>45 years & 27040 (53) & 1554 (53) & 1762 (59)\\
Smoking status &  &  & \\
\hspace{1em}Never & 28271 (56) & 1609 (55) & 1593 (54)\\
\hspace{1em}Former & 19860 (39) & 1185 (40) & 1259 (43)\\
\hspace{1em}Current & 2487 (5) & 141 (5) & 110 (4)\\
Alcohol status &  &  & \\
\hspace{1em}Never & 1565 (3) & 74 (3) & 103 (4)\\
\hspace{1em}Past & 9751 (20) & 573 (20) & 472 (16)\\
\hspace{1em}Current & 36879 (77) & 2157 (77) & 2305 (80)\\
Education &  &  & \\
\hspace{1em}<HS degree & 627 (1) & 34 (1) & 30 (1)\\
\hspace{1em}Completed HS & 7177 (14) & 455 (15) & 397 (13)\\
\hspace{1em}Some college, no degree & 9957 (20) & 573 (19) & 534 (18)\\
\hspace{1em}Associate or technical degree & 7224 (14) & 420 (14) & 405 (14)\\
\hspace{1em}Bachelor's degree & 13714 (27) & 776 (26) & 826 (28)\\
\hspace{1em}Graduate level degree & 12170 (24) & 694 (24) & 781 (26)\\
Hormone replacement therapy (ever Yes/No) & 29275 (63) & 1659 (61) & 1736 (64)\\
Birth control (ever Yes/No) & 43118 (85) & 2515 (86) & 2491 (84)\\
Age at first birth (years) &  &  & \\
no birth & 9293 (18) & 551 (19) & 547 (18)\\
\hspace{1em}<20 & 9791 (19) & 575 (19) & 540 (18)\\
\hspace{1em}>20-24 & 12808 (25) & 751 (25) & 759 (26)\\
\hspace{1em}>24-29 & 11571 (23) & 675 (23) & 662 (22)\\
\hspace{1em}>29-55 & 7421 (15) & 400 (14) & 466 (16)\\
\hspace{1em}Race/ethnicity &  &  & \\
\hspace{1em}Non-Hispanic White & 42558 (84) & 2463 (83) & 2554 (86)\\
\hspace{1em}Non-Hispanic Black & 4462 (9) & 266 (9) & 222 (7)\\
\hspace{1em}Hispanic & 2515 (5) & 144 (5) & 113 (4)\\
\hspace{1em}Other & 1334 (3) & 79 (3) & 84 (3)\\
BMI categories (kg/m$^2$) &  &  & \\
\hspace{1em}< 18.5 & 563 (1) & 25 (1) & 26 (1)\\
\hspace{1em}18.5-24.9 & 18875 (37) & 1111 (38) & 1056 (36)\\
\hspace{1em}25.0-29.9 & 16149 (32) & 934 (32) & 953 (32)\\
\hspace{1em}30.0-34.9 & 8800 (17) & 509 (17) & 551 (19)\\
\hspace{1em}35.0-39.9 & 3958 (8) & 230 (8) & 232 (8)\\
\hspace{1em}40.0 + & 2519 (5) & 140 (5) & 156 (5)\\
\bottomrule
\end{longtable}

\clearpage
\newpage

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-5}Breast cancer risk associated with increasing levels of iron-related biomarkers, Sister Study case-cohort sample.}
\centering
\begin{threeparttable}
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{lllll>{\centering\arraybackslash}p{4cm}}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{4}{c}{Quartile of iron-related biomarker} & \multicolumn{1}{c}{Linear trend over quartiles$^c$} \\
\cmidrule(l{3pt}r{3pt}){2-5} \cmidrule(l{3pt}r{3pt}){6-6}
Biomarkers & Quartile 1 & Quartile 2 & Quartile 3 & Quartile 4 &  \\
\midrule
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Iron ($\mu$g/dL)}}\\
\hspace{1em}Median & 63 & 85 & 103 & 133 & \\
\hspace{1em}Ranges & [5,74] & (74,93] & (93,115] & (115,340] & \\
\hspace{1em}Unadjusted & ref & 1.15 (0.99, 1.33) & 1.08 (0.93, 1.25) & 1.14 (0.98, 1.32) & 1.03 (0.99, 1.08)\\
\hspace{1em}Adjusted$^a$ & ref & 1.07 (0.91, 1.26) & 1.08 (0.92, 1.27) & 1.06 (0.90, 1.25) & 1.02 (0.97, 1.07)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Ferritin$^b$ ($\mu$g/dL)}}\\
\hspace{1em}Median & 22 & 50 & 88 & 157 & \\
\hspace{1em}Ranges & [5,36.25] & (36.25,67] & (67,113] & (113,1625] & \\
\hspace{1em}Unadjusted & ref & 1.05 (0.90, 1.21) & 1.09 (0.93, 1.26) & 1.06 (0.91, 1.23) & 1.02 (0.97, 1.07)\\
\hspace{1em}Adjusted$^a$ & ref & 0.99 (0.84, 1.17) & 1.05 (0.89, 1.24) & 1.03 (0.87, 1.23) & 1.02 (0.96, 1.07)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Transferrin saturation (\%)}}\\
\hspace{1em}Median & 19 & 26 & 33 & 42 & \\
\hspace{1em}Ranges & [2,22] & (22,29] & (29,36] & (36,90] & \\
\hspace{1em}Unadjusted & ref & 1.01 (0.88, 1.17) & 1.10 (0.95, 1.28) & 1.02 (0.88, 1.19) & 1.02 (0.97, 1.06)\\
\hspace{1em}Adjusted$^a$ & ref & 0.92 (0.78, 1.07) & 1.06 (0.89, 1.25) & 0.94 (0.80, 1.12) & 1.00 (0.95, 1.05)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{First principal component$^d$}}\\
\hspace{1em}Median & -1.5 & -0.3 & 0.5 & 1.5 & \\
\hspace{1em}Ranges & [-9.9,-0.799] & (-0.799,0.147] & (0.147,0.976] & (0.976,5.12] & \\
\hspace{1em}Unadjusted & ref & 1.18 (1.02, 1.37) & 1.11 (0.95, 1.28) & 1.11 (0.96, 1.29) & 1.03 (0.98, 1.07)\\
\hspace{1em}Adjusted$^a$ & ref & 1.12 (0.95, 1.32) & 1.04 (0.88, 1.23) & 1.06 (0.90, 1.25) & 1.01 (0.96, 1.06)\\
\bottomrule
\end{tabular}}
\begin{tablenotes}
\item[a] Adjusted for  baseline smoking, alcohol, education,  HRT, age at menarche, age at first birth, oral contraceptive use, menopause status, BMI, and a product term between the last two variables.
\item[b] log transformed
\item[c] Iron covariate in quartile units
\item[d] The first principal component explains 72\% of the variance and represents loadings of 0.63, 0.40, and 0.66 for the iron, ferritin and transferrin saturation measures, respectively.
\end{tablenotes}
\end{threeparttable}
\end{table}

\hypertarget{supplement}{%
\section{Supplement}\label{supplement}}

\hypertarget{refs}{}

\beginsupplement

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-13}Breast cancer hazard ratios by serum iron covariate (restricted to first four years of follow-up)}
\centering
\begin{threeparttable}
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{lllll>{\centering\arraybackslash}p{4cm}}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{4}{c}{Quartile of iron-related biomarker} & \multicolumn{1}{c}{Linear trend over quartiles$^c$} \\
\cmidrule(l{3pt}r{3pt}){2-5} \cmidrule(l{3pt}r{3pt}){6-6}
Biomarkers & Quartile 1 & Quartile 2 & Quartile 3 & Quartile 4 &  \\
\midrule
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Iron ($\mu$g/dL)}}\\
\hspace{1em}Median & 63 & 85 & 103 & 133 & \\
\hspace{1em}Ranges & [5,74] & (74,93] & (93,115] & (115,340] & \\
\hspace{1em}Unadjusted & ref & 1.00 (0.83, 1.21) & 1.02 (0.85, 1.24) & 1.08 (0.90, 1.31) & 1.03 (0.97, 1.09)\\
\hspace{1em}Adjusted$^a$ & ref & 0.98 (0.80, 1.21) & 1.04 (0.84, 1.28) & 1.03 (0.84, 1.27) & 1.01 (0.95, 1.08)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Ferritin$^b$ ($\mu$g/dL)}}\\
\hspace{1em}Median & 21 & 50 & 87 & 157 & \\
\hspace{1em}Ranges & [5,36] & (36,67] & (67,113] & (113,1625] & \\
\hspace{1em}Unadjusted & ref & 0.93 (0.77, 1.13) & 0.95 (0.78, 1.15) & 1.02 (0.84, 1.24) & 1.01 (0.95, 1.08)\\
\hspace{1em}Adjusted$^a$ & ref & 0.94 (0.76, 1.16) & 0.99 (0.80, 1.22) & 1.01 (0.81, 1.25) & 1.01 (0.94, 1.08)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Transferrin saturation (\%)}}\\
\hspace{1em}Median & 19 & 27 & 33 & 42 & \\
\hspace{1em}Ranges & [2,23] & (23,29] & (29,36] & (36,90] & \\
\hspace{1em}Unadjusted & ref & 1.01 (0.84, 1.22) & 1.07 (0.88, 1.28) & 1.03 (0.86, 1.24) & 1.02 (0.96, 1.08)\\
\hspace{1em}Adjusted$^a$ & ref & 0.96 (0.78, 1.17) & 1.08 (0.88, 1.33) & 0.94 (0.77, 1.16) & 1.00 (0.93, 1.06)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{First principal component$^d$}}\\
\hspace{1em}Median & -1.5 & -0.3 & 0.6 & 1.5 & \\
\hspace{1em}Ranges & [-9.82,-0.786] & (-0.786,0.156] & (0.156,0.977] & (0.977,5.11] & \\
\hspace{1em}Unadjusted & ref & 1.06 (0.87, 1.28) & 1.08 (0.89, 1.31) & 1.08 (0.89, 1.31) & 1.03 (0.97, 1.09)\\
\hspace{1em}Adjusted$^a$ & ref & 1.02 (0.83, 1.26) & 1.04 (0.85, 1.29) & 1.00 (0.81, 1.24) & 1.00 (0.94, 1.07)\\
\bottomrule
\end{tabular}}
\begin{tablenotes}
\item[a] Adjusted for  baseline smoking, alcohol, education,  HRT, age at menarche, age at first birth, oral contraceptive use, menopause status, BMI, and a product term between the last two variables.
\item[b] log transformed
\item[c] Iron covariate in quartile units
\item[d] The first principal component explains 72\% of the variance and represents loadings of 0.63, 0.40, and 0.66 for the iron, ferritin and transferrin saturation measures, respectively.
\end{tablenotes}
\end{threeparttable}
\end{table}

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-13}Breast cancer hazard ratios by serum iron covariate (omitting first two years of follow-up)}
\centering
\begin{threeparttable}
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{lllll>{\centering\arraybackslash}p{4cm}}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{4}{c}{Quartile of iron-related biomarker} & \multicolumn{1}{c}{Linear trend over quartiles$^c$} \\
\cmidrule(l{3pt}r{3pt}){2-5} \cmidrule(l{3pt}r{3pt}){6-6}
Biomarkers & Quartile 1 & Quartile 2 & Quartile 3 & Quartile 4 &  \\
\midrule
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Iron ($\mu$g/dL)}}\\
\hspace{1em}Median & 63 & 84 & 103 & 133 & \\
\hspace{1em}Ranges & [5,74] & (74,93] & (93,115] & (115,340] & \\
\hspace{1em}Unadjusted & ref & 1.12 (0.96, 1.31) & 1.11 (0.95, 1.31) & 1.09 (0.93, 1.28) & 1.02 (0.97, 1.08)\\
\hspace{1em}Adjusted$^a$ & ref & 1.14 (0.95, 1.35) & 1.16 (0.97, 1.38) & 1.10 (0.92, 1.32) & 1.03 (0.97, 1.09)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Ferritin$^b$ ($\mu$g/dL)}}\\
\hspace{1em}Median & 22 & 51 & 88 & 156 & \\
\hspace{1em}Ranges & [5,36] & (36,67] & (67,113] & (113,1404] & \\
\hspace{1em}Unadjusted & ref & 1.00 (0.85, 1.17) & 1.06 (0.90, 1.25) & 1.11 (0.94, 1.31) & 1.04 (0.99, 1.09)\\
\hspace{1em}Adjusted$^a$ & ref & 1.00 (0.83, 1.19) & 1.07 (0.89, 1.28) & 1.07 (0.89, 1.29) & 1.03 (0.97, 1.09)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Transferrin saturation (\%)}}\\
\hspace{1em}Median & 19 & 26 & 33 & 42 & \\
\hspace{1em}Ranges & [2,22] & (22,29] & (29,36] & (36,87] & \\
\hspace{1em}Unadjusted & ref & 0.97 (0.83, 1.13) & 1.05 (0.90, 1.24) & 0.99 (0.84, 1.17) & 1.01 (0.96, 1.06)\\
\hspace{1em}Adjusted$^a$ & ref & 0.94 (0.79, 1.11) & 1.10 (0.92, 1.31) & 0.98 (0.82, 1.17) & 1.01 (0.95, 1.07)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{First principal component$^d$}}\\
\hspace{1em}Median & -1.5 & -0.3 & 0.6 & 1.5 & \\
\hspace{1em}Ranges & [-9.93,-0.799] & (-0.799,0.146] & (0.146,0.979] & (0.979,5.13] & \\
\hspace{1em}Unadjusted & ref & 1.14 (0.97, 1.33) & 1.06 (0.90, 1.24) & 1.10 (0.93, 1.29) & 1.02 (0.97, 1.07)\\
\hspace{1em}Adjusted$^a$ & ref & 1.18 (0.99, 1.40) & 1.04 (0.88, 1.25) & 1.11 (0.93, 1.33) & 1.02 (0.96, 1.08)\\
\bottomrule
\end{tabular}}
\begin{tablenotes}
\item[a] Adjusted for  baseline smoking, alcohol, education,  HRT, age at menarche, age at first birth, oral contraceptive use, menopause status, BMI, and a product term between the last two variables.
\item[b] log transformed
\item[c] Iron covariate in quartile units
\item[d] The first principal component explains 72\% of the variance and represents loadings of 0.63, 0.40, and 0.66 for the iron, ferritin and transferrin saturation measures, respectively.
\end{tablenotes}
\end{threeparttable}
\end{table}

\clearpage
\newpage

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-16}Breast cancer hazard ratios by serum iron covariate and race/ethnic subgroups.}
\centering
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{threeparttable}
\begin{tabular}[t]{l>{\raggedright\arraybackslash}p{3cm}lllll>{\centering\arraybackslash}p{4cm}}
\toprule
\multicolumn{1}{c}{} & \multicolumn{1}{c}{} & \multicolumn{1}{c}{} & \multicolumn{4}{c}{Quartile of iron-related biomarker} & \multicolumn{1}{c}{Linear trend over quartiles$^c$} \\
\cmidrule(l{3pt}r{3pt}){4-7} \cmidrule(l{3pt}r{3pt}){8-8}
Iron & Race/ethnicity & Values & ref & Q2 & Q3 & Q4 & \\
\midrule
 &  & Median & 55 & 72 & 87 & 108 & \\
\cmidrule{3-8}
 &  & Ranges & [20,66] & (66,79] & (79,96.2] & (96.2,236] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.00 (0.58, 1.73) & 0.90 (0.53, 1.56) & 1.08 (0.63, 1.86) & 1.02 (0.86, 1.21)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Black, non-Hispanic (n=470, subcohort n=262)} & Adjusted$^a$ HR (95\% CI) & ref & 1.01 (0.58, 1.76) & 0.92 (0.53, 1.59) & 1.09 (0.63, 1.91) & 1.02 (0.85, 1.21)\\
\cmidrule{2-8}
 &  & Median & 66 & 85 & 102 & 136 & \\
\cmidrule{3-8}
 &  & Ranges & [21,74] & (74,92] & (92,114] & (114,223] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.03 (0.48, 2.22) & 0.58 (0.26, 1.27) & 0.80 (0.38, 1.68) & 0.88 (0.70, 1.12)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Hispanic (n=236, subcohort n=135)} & Adjusted$^a$ HR (95\% CI) & ref & 1.01 (0.46, 2.20) & 0.58 (0.26, 1.30) & 0.79 (0.37, 1.69) & 0.89 (0.69, 1.14)\\
\cmidrule{2-8}
 &  & Median & 64 & 86 & 105 & 134 & \\
\cmidrule{3-8}
 &  & Ranges & [5,76] & (76,94] & (94,117] & (117,340] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.13 (0.96, 1.33) & 1.09 (0.93, 1.28) & 1.13 (0.96, 1.32) & 1.03 (0.98, 1.09)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash Iron ($\mu$g/dL)} & \multirow{-4}{3cm}{\raggedright\arraybackslash White, non-Hispanic (n=4881, subcohort n=2487)} & Adjusted$^a$ HR (95\% CI) & ref & 1.13 (0.96, 1.33) & 1.11 (0.94, 1.30) & 1.16 (0.98, 1.36) & 1.04 (0.99, 1.10)\\
\cmidrule{1-8}
 &  & Median & 19 & 56 & 102 & 189 & \\
\cmidrule{3-8}
 &  & Ranges & [5,38] & (38,82] & (82,134.2] & (134.2,832] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.03 (0.60, 1.80) & 1.17 (0.67, 2.02) & 1.16 (0.66, 2.02) & 1.06 (0.88, 1.26)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Black, non-Hispanic (n=470, subcohort n=262)} & Adjusted$^a$ HR (95\% CI) & ref & 1.06 (0.60, 1.87) & 1.16 (0.65, 2.06) & 1.17 (0.66, 2.06) & 1.06 (0.88, 1.26)\\
\cmidrule{2-8}
 &  & Median & 22 & 55 & 88 & 170 & \\
\cmidrule{3-8}
 &  & Ranges & [5,39] & (39,75] & (75,119.8] & (119.8,573] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 0.51 (0.23, 1.12) & 0.41 (0.18, 0.95) & 0.90 (0.40, 2.05) & 0.98 (0.75, 1.29)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Hispanic (n=236, subcohort n=135)} & Adjusted$^a$ HR (95\% CI) & ref & 0.52 (0.22, 1.21) & 0.38 (0.16, 0.92) & 0.85 (0.36, 1.99) & 0.96 (0.73, 1.27)\\
\cmidrule{2-8}
 &  & Median & 22 & 50 & 86 & 152 & \\
\cmidrule{3-8}
 &  & Ranges & [5,36] & (36,66] & (66,111] & (111,1625] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.08 (0.92, 1.27) & 1.11 (0.94, 1.30) & 1.07 (0.91, 1.27) & 1.02 (0.97, 1.08)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash Ferritin$^b$ ($\mu$g/dL)} & \multirow{-4}{3cm}{\raggedright\arraybackslash White, non-Hispanic (n=4881, subcohort n=2487)} & Adjusted$^a$ HR (95\% CI) & ref & 1.09 (0.92, 1.28) & 1.11 (0.94, 1.31) & 1.05 (0.89, 1.24) & 1.02 (0.96, 1.07)\\
\cmidrule{1-8}
 &  & Median & 17 & 23 & 28 & 36 & \\
\cmidrule{3-8}
 &  & Ranges & [5,21] & (21,25] & (25,31] & (31,64] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.04 (0.60, 1.81) & 1.04 (0.62, 1.75) & 0.94 (0.55, 1.59) & 0.98 (0.83, 1.16)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Black, non-Hispanic (n=470, subcohort n=262)} & Adjusted$^a$ HR (95\% CI) & ref & 1.05 (0.60, 1.84) & 1.04 (0.62, 1.75) & 0.93 (0.54, 1.60) & 0.98 (0.83, 1.16)\\
\cmidrule{2-8}
 &  & Median & 20 & 26 & 32 & 42 & \\
\cmidrule{3-8}
 &  & Ranges & [5,23.2] & (23.2,29] & (29,35] & (35,66] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 0.84 (0.39, 1.80) & 0.87 (0.40, 1.87) & 0.62 (0.29, 1.33) & 0.87 (0.68, 1.11)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Hispanic (n=236, subcohort n=135)} & Adjusted$^a$ HR (95\% CI) & ref & 0.81 (0.37, 1.77) & 0.83 (0.37, 1.84) & 0.61 (0.28, 1.36) & 0.87 (0.68, 1.11)\\
\cmidrule{2-8}
 &  & Median & 19 & 27 & 33 & 42 & \\
\cmidrule{3-8}
 &  & Ranges & [2,23] & (23,29] & (29,36] & (36,90] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.07 (0.91, 1.25) & 1.15 (0.98, 1.35) & 1.05 (0.90, 1.22) & 1.02 (0.97, 1.07)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash Transferrin Saturation (\%)} & \multirow{-4}{3cm}{\raggedright\arraybackslash White, non-Hispanic (n=4881, subcohort n=2487)} & Adjusted$^a$ HR (95\% CI) & ref & 1.07 (0.91, 1.26) & 1.17 (1.00, 1.38) & 1.08 (0.92, 1.27) & 1.03 (0.98, 1.09)\\
\cmidrule{1-8}
 &  & Median & -2 & -1 & 0 & 1 & \\
\cmidrule{3-8}
 &  & Ranges & [-6.89,-1.08] & (-1.08,-0.243] & (-0.243,0.467] & (0.467,3.39] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.04 (0.60, 1.81) & 1.23 (0.71, 2.11) & 0.92 (0.53, 1.60) & 0.99 (0.83, 1.18)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Black, non-Hispanic (n=470, subcohort n=262)} & Adjusted$^a$ HR (95\% CI) & ref & 1.04 (0.60, 1.82) & 1.24 (0.71, 2.14) & 0.91 (0.52, 1.60) & 0.99 (0.83, 1.18)\\
\cmidrule{2-8}
 &  & Median & -1 & -0 & 1 & 2 & \\
\cmidrule{3-8}
 &  & Ranges & [-6.64,-0.727] & (-0.727,0.204] & (0.204,1.04] & (1.04,2.99] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.10 (0.51, 2.38) & 0.71 (0.33, 1.55) & 0.69 (0.32, 1.48) & 0.86 (0.67, 1.09)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Hispanic (n=236, subcohort n=135)} & Adjusted$^a$ HR (95\% CI) & ref & 1.05 (0.48, 2.32) & 0.72 (0.33, 1.58) & 0.69 (0.32, 1.50) & 0.86 (0.67, 1.10)\\
\cmidrule{2-8}
 &  & Median & -2 & -0 & 1 & 2 & \\
\cmidrule{3-8}
 &  & Ranges & [-9.9,-0.765] & (-0.765,0.192] & (0.192,1.02] & (1.02,5.12] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.17 (1.00, 1.38) & 1.14 (0.97, 1.34) & 1.13 (0.97, 1.33) & 1.04 (0.98, 1.09)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash First principal component} & \multirow{-4}{3cm}{\raggedright\arraybackslash White, non-Hispanic (n=4881, subcohort n=2487)} & Adjusted$^a$ HR (95\% CI) & ref & 1.17 (0.99, 1.37) & 1.15 (0.97, 1.35) & 1.16 (0.98, 1.36) & 1.04 (0.99, 1.10)\\
\bottomrule
\end{tabular}
\begin{tablenotes}
\item[a] Adjusted for BMI, baseline menopause status, and a product term of these two variables. Number of adjusted factors is small due to small sample size for some groups.
\item[b] log transformed
\item[c] Iron covariate in quartile units
\end{tablenotes}
\end{threeparttable}}
\end{table}

\clearpage
\newpage

\vspace{-1em}

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-18}Breast cancer hazard ratios by serum iron covariate and BMI subgroups}
\centering
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{threeparttable}
\begin{tabular}[t]{l>{\raggedright\arraybackslash}p{3cm}lllll>{\centering\arraybackslash}p{4cm}}
\toprule
\multicolumn{1}{c}{} & \multicolumn{1}{c}{} & \multicolumn{1}{c}{} & \multicolumn{4}{c}{Quartile of iron-related biomarker} & \multicolumn{1}{c}{Linear trend over quartiles$^c$} \\
\cmidrule(l{3pt}r{3pt}){4-7} \cmidrule(l{3pt}r{3pt}){8-8}
Iron & BMI groups & Values & ref & Q2 & Q3 & Q4 & \\
\midrule
 &  & Median & 66 & 90 & 111 & 142 & \\
\cmidrule{3-8}
 &  & Ranges & [5,79] & (79,100] & (100,125] & (125,340] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.02 (0.80, 1.30) & 0.94 (0.73, 1.20) & 1.07 (0.83, 1.36) & 1.01 (0.94, 1.09)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Normal: 18.5-24.9 (n=2094, subcohort n=1105)} & Adjusted$^a$ HR (95\% CI) & ref & 0.94 (0.72, 1.23) & 0.90 (0.69, 1.17) & 1.02 (0.78, 1.33) & 1.00 (0.92, 1.09)\\
\cmidrule{2-8}
 &  & Median & 64 & 86 & 104 & 133 & \\
\cmidrule{3-8}
 &  & Ranges & [21,76] & (76,94] & (94,114] & (114,332] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 0.84 (0.65, 1.10) & 1.02 (0.78, 1.33) & 0.92 (0.70, 1.20) & 0.99 (0.91, 1.08)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Overweight: 25.0-29.9 (n=1839, subcohort n=942)} & Adjusted$^a$ HR (95\% CI) & ref & 0.82 (0.61, 1.10) & 0.99 (0.74, 1.32) & 0.81 (0.60, 1.09) & 0.96 (0.87, 1.05)\\
\cmidrule{2-8}
 &  & Median & 60 & 78 & 94 & 121 & \\
\cmidrule{3-8}
 &  & Ranges & [14,69] & (69,85] & (85,103] & (103,276] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.47 (1.11, 1.93) & 1.27 (0.97, 1.68) & 1.27 (0.96, 1.67) & 1.06 (0.97, 1.15)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash Iron$^b$ ($\mu$g/dL)} & \multirow{-4}{3cm}{\raggedright\arraybackslash Obese: 30+ (n=1760, subcohort n=889)} & Adjusted$^a$ HR (95\% CI) & ref & 1.47 (1.08, 1.99) & 1.34 (0.98, 1.82) & 1.37 (1.01, 1.86) & 1.08 (0.98, 1.19)\\
\cmidrule{1-8}
 &  & Median & 22 & 47 & 77 & 135 & \\
\cmidrule{3-8}
 &  & Ranges & [5,34] & (34,61] & (61,97] & (97,1625] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 0.96 (0.75, 1.24) & 1.02 (0.79, 1.32) & 1.06 (0.82, 1.37) & 1.02 (0.94, 1.11)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Normal: 18.5-24.9 (n=2094, subcohort n=1105)} & Adjusted$^a$ HR (95\% CI) & ref & 0.86 (0.65, 1.12) & 0.93 (0.70, 1.23) & 0.99 (0.75, 1.32) & 1.01 (0.92, 1.11)\\
\cmidrule{2-8}
 &  & Median & 22 & 53 & 90 & 152 & \\
\cmidrule{3-8}
 &  & Ranges & [5,37] & (37,70] & (70,114] & (114,1160] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 0.93 (0.71, 1.21) & 1.03 (0.79, 1.35) & 1.00 (0.76, 1.32) & 1.01 (0.93, 1.10)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Overweight: 25.0-29.9 (n=1839, subcohort n=942)} & Adjusted$^a$ HR (95\% CI) & ref & 0.96 (0.71, 1.29) & 1.18 (0.87, 1.60) & 1.06 (0.78, 1.44) & 1.04 (0.94, 1.14)\\
\cmidrule{2-8}
 &  & Median & 22 & 59 & 102 & 185 & \\
\cmidrule{3-8}
 &  & Ranges & [5,40] & (40,78.5] & (78.5,133] & (133,1404] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.27 (0.97, 1.67) & 1.15 (0.88, 1.52) & 1.30 (0.98, 1.72) & 1.07 (0.98, 1.17)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash Ferritin$^b$ ($\mu$g/dL)} & \multirow{-4}{3cm}{\raggedright\arraybackslash Obese: 30+ (n=1760, subcohort n=889)} & Adjusted$^a$ HR (95\% CI) & ref & 1.22 (0.90, 1.65) & 1.13 (0.83, 1.54) & 1.20 (0.88, 1.65) & 1.05 (0.95, 1.16)\\
\cmidrule{1-8}
 &  & Median & 20 & 28 & 35 & 45 & \\
\cmidrule{3-8}
 &  & Ranges & [2,24] & (24,31] & (31,39] & (39,90] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.20 (0.94, 1.54) & 1.03 (0.81, 1.31) & 1.17 (0.92, 1.50) & 1.03 (0.96, 1.12)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Normal: 18.5-24.9 (n=2094, subcohort n=1105)} & Adjusted$^a$ HR (95\% CI) & ref & 1.07 (0.82, 1.39) & 0.93 (0.72, 1.21) & 1.07 (0.82, 1.40) & 1.01 (0.93, 1.10)\\
\cmidrule{2-8}
 &  & Median & 20 & 26 & 33 & 42 & \\
\cmidrule{3-8}
 &  & Ranges & [5,23] & (23,29] & (29,36] & (36,87] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 0.82 (0.64, 1.07) & 1.07 (0.82, 1.39) & 0.91 (0.70, 1.19) & 1.00 (0.92, 1.09)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Overweight: 25.0-29.9 (n=1839, subcohort n=942)} & Adjusted$^a$ HR (95\% CI) & ref & 0.76 (0.57, 1.01) & 1.01 (0.76, 1.35) & 0.81 (0.60, 1.09) & 0.97 (0.88, 1.06)\\
\cmidrule{2-8}
 &  & Median & 18 & 24 & 29 & 38 & \\
\cmidrule{3-8}
 &  & Ranges & [3,21] & (21,26] & (26,32] & (32,80] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.03 (0.78, 1.35) & 1.10 (0.84, 1.43) & 1.16 (0.88, 1.53) & 1.05 (0.96, 1.15)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash Transferrin Saturation (\%)} & \multirow{-4}{3cm}{\raggedright\arraybackslash Obese: 30+ (n=1760, subcohort n=889)} & Adjusted$^a$ HR (95\% CI) & ref & 0.94 (0.70, 1.28) & 1.13 (0.84, 1.53) & 1.18 (0.87, 1.60) & 1.07 (0.97, 1.18)\\
\cmidrule{1-8}
 &  & Median & -1 & -0 & 1 & 2 & \\
\cmidrule{3-8}
 &  & Ranges & [-9.9,-0.588] & (-0.588,0.371] & (0.371,1.23] & (1.23,4.65] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.25 (0.98, 1.60) & 0.95 (0.74, 1.22) & 1.16 (0.90, 1.48) & 1.02 (0.94, 1.10)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Normal: 18.5-24.9 (n=2094, subcohort n=1105)} & Adjusted$^a$ HR (95\% CI) & ref & 1.36 (1.04, 1.78) & 0.92 (0.70, 1.20) & 1.15 (0.88, 1.50) & 1.00 (0.92, 1.09)\\
\cmidrule{2-8}
 &  & Median & -1 & -0 & 1 & 2 & \\
\cmidrule{3-8}
 &  & Ranges & [-6.71,-0.75] & (-0.75,0.193] & (0.193,0.965] & (0.965,4.87] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 0.84 (0.64, 1.10) & 1.03 (0.79, 1.35) & 0.96 (0.73, 1.25) & 1.01 (0.93, 1.10)\\
\cmidrule{3-8}
 & \multirow{-4}{3cm}{\raggedright\arraybackslash Overweight: 25.0-29.9 (n=1839, subcohort n=942)} & Adjusted$^a$ HR (95\% CI) & ref & 0.89 (0.66, 1.20) & 0.98 (0.73, 1.31) & 0.91 (0.68, 1.23) & 0.98 (0.89, 1.08)\\
\cmidrule{2-8}
 &  & Median & -2 & -1 & 0 & 1 & \\
\cmidrule{3-8}
 &  & Ranges & [-8.26,-1.02] & (-1.02,-0.098] & (-0.098,0.644] & (0.644,5.12] & \\
\cmidrule{3-8}
 &  & Unadjusted HR (95\% CI) & ref & 1.21 (0.92, 1.59) & 1.13 (0.86, 1.49) & 1.26 (0.96, 1.66) & 1.06 (0.97, 1.16)\\
\cmidrule{3-8}
\multirow{-12}{*}{\raggedright\arraybackslash First principal component} & \multirow{-4}{3cm}{\raggedright\arraybackslash Obese: 30+ (n=1760, subcohort n=889)} & Adjusted$^a$ HR (95\% CI) & ref & 1.11 (0.82, 1.52) & 1.16 (0.85, 1.58) & 1.24 (0.91, 1.68) & 1.07 (0.97, 1.18)\\
\bottomrule
\end{tabular}
\begin{tablenotes}
\item[a] Adjusted for baseline smoking, alcohol, education, HRT, age at menarche, age at first birth, oral contraceptive use, and menopause status.
\item[b] log transformed
\item[c] Iron covariate in quartile units
\end{tablenotes}
\end{threeparttable}}
\end{table}

\clearpage
\newpage

\clearpage
\newpage

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-19}Breast cancer risk associated with increasing levels of iron-related biomarkers for women with premenopausal person-time.}
\centering
\begin{threeparttable}
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{lllll>{\centering\arraybackslash}p{4cm}}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{4}{c}{Quartile of iron-related biomarker} & \multicolumn{1}{c}{Linear trend over quartiles$^c$} \\
\cmidrule(l{3pt}r{3pt}){2-5} \cmidrule(l{3pt}r{3pt}){6-6}
Biomarkers & Quartile 1 & Quartile 2 & Quartile 3 & Quartile 4 &  \\
\midrule
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Iron ($\mu$g/dL)}}\\
\hspace{1em}Median & 57 & 82 & 105 & 142 & \\
\hspace{1em}n & 451 & 462 & 449 & 431 & \\
\hspace{1em}Ranges & [5,70] & (70,93] & (93,120] & (120,276] & \\
\hspace{1em}Unadjusted & ref & 1.43 (1.03, 1.98) & 1.38 (0.99, 1.93) & 1.61 (1.16, 2.22) & 1.15 (1.03, 1.27)\\
\hspace{1em}Adjusted$^a$ & ref & 1.47 (1.01, 2.15) & 1.35 (0.92, 1.98) & 1.46 (0.99, 2.14) & 1.10 (0.98, 1.24)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Ferritin$^b$ ($\mu$g/dL)}}\\
\hspace{1em}Median & 14 & 31 & 54 & 112 & \\
\hspace{1em}n & 463 & 441 & 444 & 445 & \\
\hspace{1em}Ranges & [5,22] & (22,41] & (41,76] & (76,1625] & \\
\hspace{1em}Unadjusted & ref & 1.42 (1.03, 1.95) & 1.48 (1.07, 2.05) & 1.07 (0.77, 1.48) & 1.04 (0.94, 1.15)\\
\hspace{1em}Adjusted$^a$ & ref & 1.48 (1.02, 2.14) & 1.52 (1.05, 2.21) & 1.14 (0.78, 1.66) & 1.06 (0.95, 1.20)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Transferrin saturation (\%)}}\\
\hspace{1em}Median & 17 & 25 & 32 & 44 & \\
\hspace{1em}n & 478 & 436 & 455 & 424 & \\
\hspace{1em}Ranges & [2,21] & (21,28] & (28,37] & (37,90] & \\
\hspace{1em}Unadjusted & ref & 1.50 (1.08, 2.08) & 1.34 (0.97, 1.85) & 1.33 (0.97, 1.84) & 1.08 (0.98, 1.19)\\
\hspace{1em}Adjusted$^a$ & ref & 1.72 (1.18, 2.50) & 1.38 (0.95, 1.99) & 1.20 (0.82, 1.75) & 1.04 (0.92, 1.16)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{First principal component}}\\
\hspace{1em}Median & -1.6 & -0.3 & 0.6 & 1.6 & \\
\hspace{1em}n & 449 & 448 & 448 & 448 & \\
\hspace{1em}Ranges & [-7.96,-0.796] & (-0.796,0.201] & (0.201,1.02] & (1.02,4.85] & \\
\hspace{1em}Unadjusted & ref & 1.51 (1.09, 2.10) & 1.44 (1.03, 2.01) & 1.55 (1.13, 2.14) & 1.13 (1.02, 1.25)\\
\hspace{1em}Adjusted$^a$ & ref & 1.68 (1.15, 2.45) & 1.51 (1.03, 2.22) & 1.48 (1.02, 2.15) & 1.10 (0.98, 1.24)\\
\bottomrule
\end{tabular}}
\begin{tablenotes}
\item[a] Adjusted for  baseline smoking, alcohol, education,  HRT, age at menarche, age at first birth, oral contraceptive use, and BMI.
\item[b] log transformed
\item[c] Iron covariate in quartile units
\end{tablenotes}
\end{threeparttable}
\end{table}

\clearpage
\newpage

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-17}Breast cancer risk associated with increasing levels of iron-related biomarkers for participants who were postmenopausal at study entry}
\centering
\begin{threeparttable}
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{lllll>{\centering\arraybackslash}p{4cm}}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{4}{c}{Quartile of iron-related biomarker} & \multicolumn{1}{c}{Linear trend over quartiles$^c$} \\
\cmidrule(l{3pt}r{3pt}){2-5} \cmidrule(l{3pt}r{3pt}){6-6}
Biomarkers & Quartile 1 & Quartile 2 & Quartile 3 & Quartile 4 &  \\
\midrule
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Iron ($\mu$g/dL)}}\\
\hspace{1em}Median & 65 & 85 & 102 & 130 & \\
\hspace{1em}n & 958 & 948 & 917 & 932 & \\
\hspace{1em}Ranges & [16,76] & (76,93] & (93,113] & (113,340] & \\
\hspace{1em}Unadjusted & ref & 1.01 (0.84, 1.20) & 0.99 (0.83, 1.19) & 0.99 (0.83, 1.19) & 1.00 (0.94, 1.05)\\
\hspace{1em}Adjusted$^a$ & ref & 0.93 (0.77, 1.13) & 0.98 (0.81, 1.20) & 0.98 (0.80, 1.19) & 1.00 (0.94, 1.06)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Ferritin$^b$ ($\mu$g/dL)}}\\
\hspace{1em}Median & 32 & 65 & 102 & 174 & \\
\hspace{1em}n & 966 & 929 & 938 & 922 & \\
\hspace{1em}Ranges & [5,49] & (49,82] & (82,129] & (129,1404] & \\
\hspace{1em}Unadjusted & ref & 1.19 (1.00, 1.43) & 1.20 (1.00, 1.43) & 1.15 (0.96, 1.38) & 1.04 (0.99, 1.11)\\
\hspace{1em}Adjusted$^a$ & ref & 1.10 (0.91, 1.34) & 1.20 (0.99, 1.46) & 1.10 (0.90, 1.33) & 1.04 (0.98, 1.10)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Transferrin saturation (\%)}}\\
\hspace{1em}Median & 20 & 26 & 33 & 42 & \\
\hspace{1em}n & 1004 & 992 & 935 & 824 & \\
\hspace{1em}Ranges & [4,23] & (23,29] & (29,36] & (36,87] & \\
\hspace{1em}Unadjusted & ref & 0.94 (0.79, 1.12) & 1.06 (0.88, 1.26) & 0.94 (0.78, 1.13) & 0.99 (0.94, 1.05)\\
\hspace{1em}Adjusted$^a$ & ref & 0.87 (0.72, 1.05) & 1.03 (0.84, 1.25) & 0.93 (0.76, 1.14) & 1.00 (0.93, 1.06)\\
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{First principal component}}\\
\hspace{1em}Median & -1.5 & -0.3 & 0.5 & 1.5 & \\
\hspace{1em}n & 939 & 939 & 938 & 939 & \\
\hspace{1em}Ranges & [-8.53,-0.808] & (-0.808,0.115] & (0.115,0.958] & (0.958,4.7] & \\
\hspace{1em}Unadjusted & ref & 1.05 (0.88, 1.26) & 1.02 (0.85, 1.22) & 1.00 (0.83, 1.19) & 1.00 (0.94, 1.05)\\
\hspace{1em}Adjusted$^a$ & ref & 1.02 (0.84, 1.24) & 1.01 (0.83, 1.23) & 1.03 (0.84, 1.25) & 1.01 (0.95, 1.07)\\
\bottomrule
\end{tabular}}
\begin{tablenotes}
\item[a] Adjusted for  baseline smoking, alcohol, education,  HRT, age at menarche, age at first birth, oral contraceptive use, and BMI.
\item[b] log transformed
\item[c] Iron covariate in quartile units
\end{tablenotes}
\end{threeparttable}
\end{table}

\clearpage
\newpage

\clearpage
\newpage

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-17}Breast cancer hazard ratios by menopause status at baseline and body iron status extreme thresholds}
\centering
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{>{\raggedright\arraybackslash}p{12em}>{\raggedright\arraybackslash}p{12em}>{\raggedright\arraybackslash}p{12em}>{\raggedright\arraybackslash}p{12em}r}
\toprule
High/low indicator & Iron measure & Cut points for dichotomized iron measure thresholds & HR (95\% CI) & n above/below threshold\\
\midrule
\addlinespace[0.3em]
\multicolumn{5}{l}{\textbf{Postmenopausal}}\\
\hspace{1em} &  & $\leq$ 12 & 0.54 (0.37, 0.79) & 107\\
\cmidrule{3-5}
\hspace{1em} &  & $\leq$ 25 & 0.82 (0.66, 1.02) & 359\\
\cmidrule{3-5}
\hspace{1em} & \multirow[t]{-3}{12em}{\raggedright\arraybackslash Ferritin ($\mu$g / L)} & $\leq$ 45 & 0.89 (0.77, 1.04) & 873\\
\cmidrule{2-5}
\hspace{1em}\multirow[t]{-4}{12em}{\raggedright\arraybackslash Low} & Transferrin saturation (\%) & $\leq$ 20 & 1.03 (0.86, 1.23) & 576\\
\cmidrule{1-5}
\hspace{1em} & Ferritin ($\mu$g / L) & $\geq$ 300 & 1.03 (0.67, 1.59) & 85\\
\cmidrule{2-5}
\hspace{1em} &  & $\geq$ 45 & 1.36 (1.07, 1.74) & 278\\
\cmidrule{3-5}
\hspace{1em} &  & $\geq$ 50 & 1.31 (0.93, 1.85) & 137\\
\cmidrule{3-5}
\hspace{1em} &  & $\geq$ 55 & 1.05 (0.66, 1.66) & 72\\
\cmidrule{3-5}
\hspace{1em}\multirow[t]{-5}{12em}{\raggedright\arraybackslash High} & \multirow[t]{-4}{12em}{\raggedright\arraybackslash Transferrin saturation (\%)} & $\geq$ 60 & 1.24 (0.63, 2.47) & 35\\
\cmidrule{1-5}
\addlinespace[0.3em]
\multicolumn{5}{l}{\textbf{Premenopausal}}\\
\hspace{1em} &  & $\leq$ 12 & 0.65 (0.45, 0.93) & 166\\
\cmidrule{3-5}
\hspace{1em} &  & $\leq$ 25 & 0.88 (0.69, 1.12) & 477\\
\cmidrule{3-5}
\hspace{1em} & \multirow[t]{-3}{12em}{\raggedright\arraybackslash Ferritin ($\mu$g / L)} & $\leq$ 45 & 0.97 (0.77, 1.21) & 864\\
\cmidrule{2-5}
\hspace{1em}\multirow[t]{-4}{12em}{\raggedright\arraybackslash Low} & Transferrin saturation (\%) & $\leq$ 20 & 0.76 (0.58, 1.00) & 415\\
\cmidrule{1-5}
\hspace{1em} & Ferritin ($\mu$g / L) & $\geq$ 200 & 0.93 (0.47, 1.84) & 45\\
\cmidrule{2-5}
\hspace{1em} &  & $\geq$ 45 & 1.26 (0.88, 1.79) & 200\\
\cmidrule{3-5}
\hspace{1em} &  & $\geq$ 50 & 1.10 (0.69, 1.74) & 114\\
\cmidrule{3-5}
\hspace{1em} &  & $\geq$ 55 & 1.15 (0.62, 2.14) & 60\\
\cmidrule{3-5}
\hspace{1em}\multirow[t]{-5}{12em}{\raggedright\arraybackslash High} & \multirow[t]{-4}{12em}{\raggedright\arraybackslash Transferrin saturation (\%)} & $\geq$ 60 & 1.64 (0.70, 3.84) & 31\\
\bottomrule
\end{tabular}}
\end{table}

\clearpage
\newpage

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-15}Odds ratio (95\% CI) of breast cancer subtypes* by iron biomarkers in case-only sample.}
\centering
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{>{\raggedright\arraybackslash}p{15em}>{\raggedright\arraybackslash}p{10em}>{\raggedright\arraybackslash}p{10em}>{\raggedright\arraybackslash}p{10em}>{\raggedright\arraybackslash}p{10em}l}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{1}{c}{ } & \multicolumn{4}{c}{Iron biomarkers} \\
\cmidrule(l{3pt}r{3pt}){3-6}
Index group & counts & FE & FE sat & log(fertn) & PC1\\
\midrule
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{One hormone receptor subtype (negative vs positive)}}\\
\hspace{1em}ER- & ER+ (n= 2112);ER- (n= 379) & 1.00 (0.99, 1.00) & 0.99 (0.98, 1.00) & 1.04 (0.91, 1.20) & 0.97 (0.90, 1.05)\\
\hspace{1em}PR- & PR+ (n= 1739);PR- (n= 675) & 1.00 (1.00, 1.01) & 1.01 (0.99, 1.02) & 1.04 (0.89, 1.23) & 1.06 (0.97, 1.17)\\
\hspace{1em}HER2- & HER+ (n= 254);HER- (n= 1784) & 1.00 (0.99, 1.00) & 0.99 (0.99, 1.00) & 1.06 (0.95, 1.18) & 0.96 (0.90, 1.03)\\
\hline
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Subtype combination (vs HR+/HER2-, n=1548)}}\\
\hspace{1em}HR+/HER2+ or HR-/HER2+ vs HR+/HER2- & 251 & 1.00 (0.99, 1.00) & 0.99 (0.98, 1.00) & 0.97 (0.82, 1.15) & 0.93 (0.84, 1.02)\\
\hspace{1em}HR-/HER2- vs HR+/HER2- & 213 & 1.00 (0.99, 1.00) & 0.99 (0.97, 1.00) & 1.10 (0.92, 1.31) & 0.92 (0.83, 1.03)\\
\hline
\addlinespace[0.3em]
\multicolumn{6}{l}{\textbf{Invasive vs In Situ}}\\
\hspace{1em} & Invasive (n= 2169); InSitu (n= 607) & 1.00 (1.00, 1.00) & 1.00 (0.99, 1.01) & 1.00 (0.90, 1.12) & 1.02 (0.96, 1.09)\\
\bottomrule
\multicolumn{6}{l}{\textsuperscript{*} Adjusted for age at diagnosis and menopause status at baseline.}\\
\end{tabular}}
\end{table}

\clearpage
\newpage

\begin{table}[H]

\caption{\label{tab:unnamed-chunk-13}Odds ratio (95\% CI) of breast cancer stage$^a$ by iron biomarkers in case-only sample.}
\centering
\resizebox{\linewidth}{!}{
\fontsize{10}{12}\selectfont
\begin{tabular}[t]{>{\raggedright\arraybackslash}p{15em}>{\raggedright\arraybackslash}p{10em}>{\raggedright\arraybackslash}p{10em}>{\raggedright\arraybackslash}p{10em}>{\raggedright\arraybackslash}p{10em}l}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{1}{c}{ } & \multicolumn{4}{c}{Iron biomarkers} \\
\cmidrule(l{3pt}r{3pt}){3-6}
Stage (vs stage 0 (n=572)) & n & Iron & Iron saturation & Ferritin$^b$ & PC1\\
\midrule
I & 1314 & 1.00 (1.00, 1.00) & 1.00 (0.99, 1.01) & 0.98 (0.87, 1.11) & 0.97 (0.91, 1.05)\\
II & 509 & 1.00 (0.99, 1.00) & 0.99 (0.98, 1.00) & 0.94 (0.81, 1.09) & 0.91 (0.83, 0.99)\\
III & 136 & 1.00 (0.99, 1.00) & 0.99 (0.97, 1.01) & 0.86 (0.69, 1.09) & 0.89 (0.78, 1.02)\\
IV & 20 & 1.00 (0.99, 1.02) & 1.00 (0.96, 1.04) & 1.24 (0.71, 2.18) & 1.04 (0.75, 1.43)\\
X & 22 & 0.99 (0.98, 1.01) & 0.98 (0.94, 1.02) & 0.87 (0.52, 1.47) & 0.85 (0.62, 1.17)\\
\bottomrule
\multicolumn{6}{l}{\textsuperscript{a} Adjusted for age at diagnosis and menopause status at baseline.}\\
\multicolumn{6}{l}{\textsuperscript{b} log transformed}\\
\end{tabular}}
\end{table}

\clearpage
\newpage

Supplemental text regarding sample handling and laboratory assessments

The Advanced Research and Diagnostic Laboratory at the University of
Minnesota acted as the central laboratory for this study, receiving
7,621 serum samples in straws in a frozen state packaged on dry ice in
goblets of 100 samples per goblet. Samples were stored frozen at -80C
until testing. To prepare samples for analysis the straw samples were
thawed to room temperature, then the straw was cut with a scissor and
the sample expelled into a labelled cryovial and capped. Scissors were
cleaned with an alcohol pad between each sample. Vials were mixed by
inversion immediately before testing. Analysis was performed on the
Roche Cobas 6000 Chemistry analyzer (Roche Diagnostics, Mannheim,
Germany) using Roche reagents and calibrators. Test methodologies and
inter-assay coefficient of variation were as follows. Iron is a
colorimetric FerroZine end-point assay with an interassay CV of 2.5\% at
a concentration 77 ug/dL. Ferritin is particle enhanced
immunoturbidimetric assay with an interassay CV of 2.8\% at a
concentration of 259 ug/L. Unsaturated Iron Binding Capacity (UIBC) is a
colorimetric assay with an inter-assay CV of 3.3\% at a concentration of
239 ug/dL. All samples had serum indices measurements for hemolysis,
icterus and lipemia performed on the Roche Cobas 6000 analyzer by
spectrophotometric method. Each assay has manufacture defined thresholds
for each indice and results were not reported if this threshold was
exceeded. Two levels of quality control were analyzed twice per day,
once at the beginning of daily testing and once at the end. One quality
control was a laboratory developed pooled serum sample and the other a
Roche Precipath U commercially available product. Assay calibration was
performed per manufacture specifications using manufacturer calibrators.
Sample results were reported to the laboratory information system via
electronic instrument interface only after quality control and
calibration results were deemed acceptable per laboratory and
manufacture standards.

Results that could not be reported were primarily due to sample
hemolysis. Our Cobas analyzer is programmed to automatically perform
specimen integrity checks for hemolysis, lipemia and icterus. The UIBC
assay is particularly sensitive to hemolysis and has the lowest
hemolysis index threshold for acceptability which is why more UIBC test
results were not reported.

\end{document}
